Impact of COVID-19 on Stroke, and TIA Admission Rates, and Prognosis
The admission rates of ischemic stroke and TIA were lower during the first weeks of the 2020 COVID-19 lockdown compared with those of 2017-2019.
The admission rates of ischemic stroke and TIA were lower during the first weeks of the 2020 COVID-19 lockdown compared with those of 2017-2019.
Study authors compared the safety and efficacy of oral anticoagulants vs antiplatelets in patients with stroke and supracardiac atherosclerosis.
Ticagrelor-aspirin is associated with a reduced risk for the composite of stroke or death within 30 days of mild-to-moderate acute noncardioembolic ischemic stroke or TIA.
A panel prepared a comprehensive set of practice implications for clinicians caring for adults with acute ischemic stroke with confirmed or suspected of having COVID-19.
Patients with transient ischemic attack with high brain natriuretic peptide values are more likely to have atrial fibrillation.
The combination of higher serum oxLDL and LDL levels was found to be associated with an increased risk for recurrent stroke and poor functional outcomes in patients who have had minor stroke or are at high risk for TIAs.
Discontinuation of vitamin K antagonist oral anticoagulant therapy was associated with an elevated risk for stroke or transient ischemic attack in patients newly diagnosed with nonvalvular atrial fibrillation.
In patients with ischemic stroke and TIA there is a significant gap between cerebrovascular risk factors control and real-world stroke prevention.
Blood biomarkers currently do not have diagnostic value for patients with suspected TIA, indicating that the sudden onset of symptoms and “onset in full intensity” are still the most valuable clinical predictors of TIA and minor stroke.
For patients with ischemic stroke or transient ischemic attack (TIA) with evidence of atherosclerosis, those with a target low-density lipoprotein (LDL) cholesterol level of less than 70 mg/dL have a lower risk for cardiovascular events.